Markets

Summit Therapeutics (SMMT) Catches Eye: Stock Jumps 8.9%

Summit Therapeutics plc SMMT was a big mover last session, as the company saw its shares rise nearly 9% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company—as the stock is now up 83.3% in the past one-month time frame.

The company has seen one positive estimate revision in the past few weeks, while its Zacks Consensus Estimate for the current quarter has also moved higher over the past few weeks, suggesting that more solid trading could be ahead for Summit Therapeutics. So make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road.

Summit Therapeutics currently has a Zacks Rank #1 (Strong Buy) while its Earnings ESP is positive.

Summit Therapeutics PLC Price

Summit Therapeutics PLC Price

Summit Therapeutics PLC price | Summit Therapeutics PLC Quote

Another stock worth considering in the Medical - Drugs industry is Cumberland Pharmaceuticals Inc. CPIX which carries a Zacks Rank #1. You can see the complete list of today’s Zacks #1 Rank stocks here.

Looking for Stocks with Skyrocketing Upside?

Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.

Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.

See the pot trades we're targeting>>


Click to get this free report


Cumberland Pharmaceuticals Inc. (CPIX): Free Stock Analysis Report

Summit Therapeutics PLC (SMMT): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Latest Markets Videos

Zacks

Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

Learn More